Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A framework for genomic biomarker actionability and its use in clinical decision making

22 Oct 2014

Abstract excerpt

The increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e.g. BRAF mutations in melanoma), standards exist that outline treatments for individuals harboring aberrations in the biomarker; however for the vast majority of genomic abnormalities, few guidelines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25593991
DOI: 10.18632/oncoscience.90

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A framework for genomic biomarker actionability and its use in clinical decision makingPMID 25593991Read ↗

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.Semantic proximity Read ↗

Data resources for the identification and interpretation of actionable mutations by clinicians.Semantic proximity Read ↗

Physician interpretation of genomic test results and treatment selection.Semantic proximity Read ↗

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Semantic proximity Read ↗

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersSemantic proximity Read ↗

Clinical Actionability of Genes in Gastrointestinal TumorsSemantic proximity Read ↗

A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation.Semantic proximity Read ↗

Clinical interpretation of integrative molecular profiles to guide precision cancer medicineSemantic proximity Read ↗

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.Semantic proximity Read ↗

Defining actionable mutations for oncology therapeutic development.Semantic proximity Read ↗

Determination of the practical utility of ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): mapping OncoKB level 1 alterations using ESCATSemantic proximity Read ↗

Genomic testing in oncology to improve clinical outcomes while optimizing utilization: the evolution of diagnostic testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.